Retatrutide

Retatrutide (code name LY-3437943) is a synthetic single-molecule peptide compound classed as a triple-acting incretin receptor agonist. It is a 39-amino-acid chain with an attached fatty acid side chain (CAS 2381089-83-2). Its main mechanism of interest is the ability to bind simultaneously to three G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCGR) receptors. Cell and in vitro models analyse how this triple binding affects receptor activation and intracellular signalling pathways. This information is provided for the scientific research context only.

In the laboratory, this compound is used as a tool for studying metabolic signalling mechanisms in vitro. Cell models monitor receptor activation and intracellular signalling pathways, for example cAMP accumulation, after activation of the GIP, GLP-1 and glucagon receptors. Such models are used in research on energy metabolism and glucose homeostasis signalling. The in vitro receptor pharmacology of LY-3437943 (its relative potency at all three receptors) has been described in a peer-reviewed paper (Coskun et al., Cell Metabolism, 2022). This information is provided for research context only and is not an instruction for use.

The product is supplied as a lyophilised (freeze-dried) powder of ≥99% purity (HPLC). Each vial contains 10 mg or 30 mg of the active substance, retatrutide. For laboratory use, the powder is reconstituted in bacteriostatic water, which is sold separately. The solvent is run slowly onto the side of the vial, and the vial is swirled gently until the powder has fully dissolved – it is not shaken, so as not to damage the peptide structure.

Unopened vials of dry lyophilised powder should be kept in a refrigerator at +2 to +8 °C, protected from light. For longer storage, a freezer (−20 °C) is recommended. Keep the reconstituted solution (dissolved in bacteriostatic water) refrigerated and use it within the time set out in the research protocol. Avoid repeated thaw–freeze cycles to preserve the stability of the peptide.

Because retatrutide is a triple-acting GIP / GLP-1 / glucagon receptor agonist, in comparative laboratory studies it is most often analysed alongside other incretin-system compounds – for example, mono-agonists (GLP-1) or dual-acting (GIP / GLP-1) agonists – to compare receptor activation profiles in in vitro models. Such experiments combine receptor signalling (cAMP) measurements with cellular metabolic markers. The specific combination depends on the research protocol; no dosing or usage recommendations are given.

Absolutely not. This product is sold exclusively for laboratory research and scientific experiments. It is not intended for human or animal consumption and is not a medicine, dietary supplement or cosmetic product.